Security
Stoke Therapeutics, Inc. Common Stock · STOK
STOKNASDAQCommon stockCurrentCIK 1623526Updated Oct 4, 2026
Name history
ASOthera Pharmaceuticals, Inc. · through Nov 24, 2014
STOK price & chart
Loading TradingView…
NASDAQ:STOK on TradingView ↗About the company
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal
In the news
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) News provided by Purcell & Lefkowitz LLP Aug 18, 2025, 08:45 ET Share this article Share to X Share this article Share to X NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Purcell & Lef ↗
Recent filings
SCHEDULE 13G - filed by BIOTECHNOLOGY VALUE FUND L P regarding Stoke Therapeutics, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
SCHEDULE 13G/A - filed by Lynx1 Capital Management LP regarding Stoke Therapeutics, Inc.
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 418,434,000Source | 271,555,000Source | 228,342,000Source | 256,067,000Source |
| Property, Plant and Equipment, NetUSD | 3,146,000Source | 3,909,000Source | 5,823,000Source | 6,675,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 84,220,000Source | 127,983,000Source | 191,442,000Source | 113,556,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,936,000Source | — | — | — |
| Assets, CurrentUSD | 305,700,000Source | 232,756,000Source | 215,339,000Source | 244,070,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,101,000Source | 4,345,000Source | 6,611,000Source | 4,753,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 65,977,000Source | 42,534,000Source | 68,777,000Source | 71,218,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 5,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 849,624,000Source | 719,997,000Source | 561,433,000Source | 483,170,000Source |
| Retained Earnings (Accumulated Deficit)USD | -497,715,000Source | -490,830,000Source | -401,849,000Source | -297,150,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 543,000Source | -151,000Source | -24,000Source | -1,175,000Source |
| Stockholders' Equity Attributable to ParentUSD | 352,457,000Source | 229,021,000Source | 159,565,000Source | 184,849,000Source |
| Liabilities and EquityUSD | 418,434,000Source | 271,555,000Source | 228,342,000Source | 256,067,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 57,875,000Source | 40,056,000Source | 30,819,000Source | 31,394,000Source |
| Operating Lease, Liability, CurrentUSD | 3,007,000Source | 2,322,000Source | 2,062,000Source | 2,359,000Source |
| Accounts Payable, CurrentUSD | 4,939,000Source | 2,498,000Source | 1,695,000Source | 766,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,141,000Source | 2,452,000Source | 4,773,000Source | 2,717,000Source |
| Other Liabilities, NoncurrentUSD | 1,141,000Source | 2,478,000Source | 4,884,000Source | 2,968,000Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 11,901,000Source | 18,991,000Source | 15,309,000Source | 14,880,000Source |
| Deferred Revenue, NoncurrentUSD | 6,961,000Source | — | 33,074,000Source | 36,856,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -6,885,000Source | -88,981,000Source | -104,699,000Source | -101,067,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 32,238,000Source | 27,470,000Source | 25,257,000Source | 22,854,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 4,268,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 45,585,000Source | -86,851,000Source | -81,067,000Source | -31,866,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -186,812,000Source | -107,475,000Source | 105,946,000Source | -45,882,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 670,000Source | 203,000Source | 1,616,000Source | 3,962,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 97,389,000Source | 131,094,000Source | 53,007,000Source | 46,409,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | 0Source | 1,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -43,838,000Source | -63,232,000Source | 77,886,000Source | -31,339,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 573,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 32,238,000Source | 27,470,000Source | 25,257,000Source | 22,854,000Source |
| DepreciationUSD | 1,770,000Source | 2,177,000Source | 2,469,000Source | 1,546,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -145,000Source | — | -1,000Source | — |
| General and Administrative ExpenseUSD | — | 48,794,000Source | 41,322,000Source | 38,924,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | 13,765,000Source | 12,664,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -6,885,000Source | -88,981,000Source | -104,699,000Source | -101,067,000Source |
| Nonoperating Income (Expense)USD | 13,705,000Source | 12,391,000Source | 10,074,000Source | 3,289,000Source |
| Operating ExpensesUSD | 205,010,000Source | 137,927,000Source | 123,553,000Source | 116,761,000Source |
| Operating Lease, Impairment LossUSD | 696,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | -51,000Source | -247,000Source | 166,000Source | 167,000Source |
| Proceeds from Stock Options ExercisedUSD | 8,603,000Source | 1,722,000Source | 371,000Source | 494,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 184,420,000Source | 36,555,000Source | 8,780,000Source | 12,405,000Source |
| Selling, General and Administrative ExpenseUSD | 67,088,000Source | — | — | — |
| Operating Income (Loss)USD | -20,590,000Source | -101,372,000Source | -114,773,000Source | -104,356,000Source |
| Other Nonoperating Income (Expense)USD | -51,000Source | -247,000Source | 166,000Source | 167,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -6,885,000Source | -88,981,000Source | -104,699,000Source | -101,067,000Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -1.65Source | -2.38Source | -2.6Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -1.65Source | -2.38Source | -2.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 59,219,184Source | 54,008,883Source | 43,994,862Source | 38,897,442Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 59,219,184Source | 54,008,883Source | 43,994,862Source | 38,897,442Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | — | 48,794,000Source | 41,322,000Source | 38,924,000Source |
| Interest ExpenseUSD | 9,000Source | 26,000Source | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 13,756,000Source | 12,638,000Source | 9,908,000Source | 3,122,000Source |
| Investment Income, InterestUSD | 13,765,000Source | 12,664,000Source | — | — |
| Nonoperating Income (Expense)USD | 13,705,000Source | 12,391,000Source | 10,074,000Source | 3,289,000Source |
| Operating ExpensesUSD | 205,010,000Source | 137,927,000Source | 123,553,000Source | 116,761,000Source |
| Research and Development ExpenseUSD | 137,922,000Source | 89,133,000Source | 82,231,000Source | 77,837,000Source |
Offerings
Registration 333-294402
Filing attachments
d63235dex991.htm · S-8 · 2026-08-03
Exhibit 99.1 S TOKE T HERAPEUTICS, I NC. 2023 I NDUCEMENT P LAN AMENDED : M AY 28, 2026 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance through the grant of Awards. Capitalized terms not def…
Read attachment ↗stok-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 stok-ex99_1.htm EX-99.1 EX-99.1 EX 99.1 Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates - Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 - - Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 - - Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort;…
Read attachment ↗d924679dex991.htm · 8-K · 2026-06-30
EX-99.1 2 d924679dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027 - - Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027 - BEDFORD, Mass.…
Read attachment ↗stok-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 stok-ex99_1.htm EX-99.1 EX-99.1 Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates - New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome - - Statistically significant improvements in cognition and behavior demonstrated at 1, 2, 3 and 4 years of treatment compar…
Read attachment ↗d63742dex991.htm · 8-K · 2026-04-07
EX-99.1 2 d63742dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Stoke Therapeutics Appoints Clare Kahn, Ph. D., to its Board of Directors BEDFORD, Mass., April 7, 2026 - Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company a…
Read attachment ↗d122133dex42.htm · S-3ASR · 2026-03-18
Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] STOKE THERAPEUTICS, INC. [If applicable, insert - FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % AND THE ISSUE DATE IS ] [IF THE SECURITY IS A GLOBAL SECURITY, INSERT - T…
Read attachment ↗